Genetic evidence that SMAD2 is not required for gonadal tumor development in inhibin-deficient mice. Academic Article uri icon


  • BACKGROUND: Inhibin is a tumor-suppressor and activin antagonist. Inhibin-deficient mice develop gonadal tumors and a cachexia wasting syndrome due to enhanced activin signaling. Because activins signal through SMAD2 and SMAD3 in vitro and loss of SMAD3 attenuates ovarian tumor development in inhibin-deficient females, we sought to determine the role of SMAD2 in the development of ovarian tumors originating from the granulosa cell lineage. METHODS: Using an inhibin alpha null mouse model and a conditional knockout strategy, double conditional knockout mice of Smad2 and inhibin alpha were generated in the current study. The survival rate and development of gonadal tumors and the accompanying cachexia wasting syndrome were monitored. RESULTS: Nearly identical to the controls, the Smad2 and inhibin alpha double knockout mice succumbed to weight loss, aggressive tumor progression, and death. Furthermore, elevated activin levels and activin-induced pathologies in the liver and stomach characteristic of inhibin deficiency were also observed in these mice. Our results indicate that SMAD2 ablation does not protect inhibin-deficient females from the development of ovarian tumors or the cachexia wasting syndrome. CONCLUSIONS: SMAD2 is not required for mediating tumorigenic signals of activin in ovarian tumor development caused by loss of inhibin.

published proceedings

  • Reprod Biol Endocrinol

author list (cited authors)

  • Rajanahally, S., Agno, J. E., Nalam, R. L., Weinstein, M. B., Loveland, K. L., Matzuk, M. M., & Li, Q.

citation count

  • 11

complete list of authors

  • Rajanahally, Saneal||Agno, Julio E||Nalam, Roopa L||Weinstein, Michael B||Loveland, Kate L||Matzuk, Martin M||Li, Qinglei

publication date

  • December 2010